Lintuzumab (HUM-195) is a humanized monoclonal antibody targeting CD33, designed to modulate immune responses in acute myeloid leukemia (AML). By reducing the production of TNF??-induced pro-inflammatory cytokines and chemokines, Lintuzumab effectively suppresses inflammatory pathways in AML cells. It facilitates tumor cell eradication via mechanisms including antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), demonstrating efficacy against both multidrug-resistant (MDR) and non-resistant AML cell lines, as well as primary samples from AML patients. In vivo studies have shown that Lintuzumab significantly enhances survival rates and diminishes tumor burden in murine models, highlighting its potential as a therapeutic agent in oncology research.
Lintuzumab (HUM-195) is a humanized monoclonal antibody targeting CD33, designed to modulate immune responses in acute myeloid leukemia (AML). By reducing the production of TNF??-induced pro-inflammatory cytokines and chemokines, Lintuzumab effectively suppresses inflammatory pathways in AML cells. It facilitates tumor cell eradication via mechanisms including antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), demonstrating efficacy against both multidrug-resistant (MDR) and non-resistant AML cell lines, as well as primary samples from AML patients. In vivo studies have shown that Lintuzumab significantly enhances survival rates and diminishes tumor burden in murine models, highlighting its potential as a therapeutic agent in oncology research.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
